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ABSTRACT

EFFECTS OF ISCHEMIA AND REPERFUSION ON MITOCHONDRIAL
PHOSPHATE UPTAKE IN RAT RENAL PROXIMAL TUBULES.
Najjar, Norman J. Siegel, Thomas O. Carpenter.

Samer

Sections of Endocrinology

and Nephrology, Department of Pediatrics, Yale University School of
Medicine, New Haven, CT.

Proximal tubular ATP is depleted in renal ischemia and is partially
replenished by subsequent reperfusion. Since ATP synthesis is dependent on
mitochondrial uptake of inorganic phosphate (Pi), we examined the effects of
ischemia and reperfusion on Pi uptake in mitochondria isolated from rat
renal proximal tubules.
Male Sprague-Dawley rats underwent bilateral renal artery occlusion
for 0 or 45 minutes.

Kidneys were collected immediately or following 30

minutes of reperfusion, and proximal tubules were harvested.

Mitochondria

were isolated and resuspended. 32p labelled Pi was added and serial aliquots
were pipetted into inhibitor-containing vials.

Mitochondrial Pi uptake was

determined at each time point from the fraction of total added radioactivity
present in mitochondria.
Mitochondrial Pi uptake in ischemic rats (0.4 +_ 0.6 nmol Pi/mg
mitochondrial

protein,

uninjured controls (13.1

mean

+_ SD) was markedly less than in either

+_ 6.3 nmol Pi/mg mito. protein) (p=0.016) or

reperfused rats (22.2 + 6.2 nmol Pi/mg mito. protein) (p=0.001). Mitochondrial

Pi uptake in reperfused rats was not significantly greater than controls
(p=0.059).
We conclude that renal proximal tubular mitochondrial Pi transport 1)
is inhibited during ischemia, when ATP is depleted; 2) recovers to at least
control levels during post-ischemic reperfusion, when ATP is replenishing.
These results suggest that mitochondrial Pi uptake in the early reflow period
is unlikely to be rate limiting for the post-ischemic regeneration of ATP.

A

possible deleterious role for Pi uptake on mitochondria during reperfusion is
discussed.
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INTRODUCTION

Ischemia and subsequent reperfusion are pathophysiologic events
common to many important clinical entities, such as myocardial infarction,
stroke and acute renal failure.

The effects of ischemia and reperfusion on

tissues, cells, subcellular organelles and biochemical substrates are therefore
being extensively investigated in many organ systems.

1) ACUTE RENAL FAILURE

Our laboratory is particularly interested in examining the
pathophysiologic processes underlying acute renal failure (ARF) and recovery
from this injury.

ARF is defined as an acute deterioration in the ability of

kidneys to maintain the homeostasis of body fluids. It is characterized by an
acute decrease in the glomerular filtration rate and a paralysis of tubular
function.

Unfortunately, the mortality rate for patients with ARF has

remained unacceptably high, exceeding 60% even in non-elderly patients
who do not have significant complications (1).

To date, most of the investigations on experimental ARF have
uncovered manipulations that could protect the glomeruli and tubules from
loss of function if applied prior to the ischemic insult.

These studies have

clarified many aspects of the pathophysiology of experimental ARF.

Their

clinical applicability has remained limited however, as physicians are usually
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faced with the task of treating ARF, not preventing it.

What is needed then,

is the development of interventions that would help overcome and/or
accelerate the recovery from ARF.

This, in turn, requires a thorough

understanding of the factors that determine the severity of the injury and
those that modulate the repair process during recovery.

Our laboratory has been actively engaged in studying the role of one of
those factors, namely cellular ATP. For a thorough review of the other
factors, the reader is referred to reference 2 which discusses in detail the
contributions to ischemic renal cell injury and repair of decreased pH,
calcium, amino acids, proteases, oxidant injury, heat shock proteins and
alterations in cell volume, cell polarity and cytoskeleton.

2) CELLULAR ATP LEVELS DURING ISCHEMIA AND REPERFUSION

The role of ATP in the energy metabolism of all cells is of paramount
importance and has been well characterized. Hydrolysis of its high energy
phosphate bond provides the driving force for many vital cell functions
including

protein

synthesis,

carbohydrate

metabolism,

maintenance of cell structure, regulation of cell volume etc.

lipogenesis,

Any insult that

depletes cellular ATP stores would prevent cells from sustaining these vital
functions and would therefore contribute to cell injury and ultimately to cell
death.

In particular ischemia, which is known to inhibit mitochondrial

oxidative phosphorylation (because of anoxia and intrinsic membrane
alterations), would be expected to lead to cellular ATP depletion.
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The study of renal cellular ATP during ischemia and reperfusion has
been greatly aided by the availability of a convenient in vivo animal model
that mimics ischemic ARF and recovery from this insult: In essence, an
animal's renal arteries are clamped for a specified amount of time and then
allowed to reperfuse. Using this model, Warnick and Lazarus (3) showed that
renal cellular ATP levels rapidly drop to 25% of their control values after 30
seconds of ischemia, then gradually decrease to 15% and 10% of their control
values after 5 minutes and 2 hours of ischemia, respectively. Using 31P-NMR
spectroscopy on in situ kidneys, Siegel et al.

(4) and Stromski et al. (5) have

similarly shown that ATP levels rapidly fall to less than 10% of their control
values within 10 minutes of ischemia, and remain low for the duration of
the 45 minute insult.

These results are in agreement with the rest of the

published data (6,7,8,9) that essentially show an 80-90% decrease in ATP levels
following 10-60 minutes of renal ischemia.

The recovery of cellular ATP during the ensuing reflow period has also
been investigated. By unclamping the renal arteries and allowing the kidneys
to reperfuse for a specified amount of time, Siegel et al. (4) and Stromski et al.
(5) have shown that ATP regeneration follows a biphasic pattern: An initial
rapid phase returns ATP levels to 50% of their pre-ischemic values after 15
minutes of reflow.

This is followed by a slower phase during which ATP

levels return to 60-65% of their pre-ischemic values after 2 hours of reflow.
Other investigators (6,8) have similarly reported a less than 50% recovery of
tissue ATP at 1 hour of reflow following a 60 minute ischemic insult.

The pattern and degree of recovery of cellular ATP is highly dependent
on the duration of the preceding ischemic interval.

Vogt and Farber (6)

showed that renal ATP levels return to 90% of their control values within 10
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minutes of reflow if the ischemic interval is less than 20 minutes. On the
other hand, there is only a 50% recovery of ATP after 1 hour of reflow if the
ischemic interval is extended beyond 25 minutes.
In the initial rapid phase of ATP repletion, this ATP is likely generated
from phosphorylation of cellular AMP and ADP (3,10).

Indeed, there is a

good correlation between ATP levels at the end of this initial rapid phase of
regeneration and total adenine nucleotide (TAN) levels at the end of the
ischemic insult (10). The size of the TAN pool (sum of ATP, ADP and AMP)
decreases with increasing duration of ischemia (3,7) as AMP is converted to
the purine nucleosides adenosine and inosine and
hypoxanthine.

the purine base

These compounds, in turn, increase during ischemia (11).

Unfortunately, they are not salvageable because they are membrane
permeable, and they, therefore, diffuse out of the cell and wash out of the
kidney upon reflow (3).
During the slower component of nucleotide regeneration, ATP is likely
derived from net cellular resynthesis (10). This process is dependent on the
residual nucleotide pool, the availability of precursor compounds and the
degree of cellular or membrane damage, which reflect the severity and
duration of the ischemic insult (10).

3) MANIPULATIONS THAT INCREASE CELLULAR ATP LEVELS DURING
REFLOW
The inability of cells to completely replete their ATP stores following a
prolonged ischemic insult undoubtedly affects their ability to recover from
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this injury, since the repair processes are all energy-dependent.

Therefore, it

seems likely that manipulations which would increase cellular ATP levels in
the post-ischemic period should help the recovery process.

Indeed, Stromski

et al. (10) found a strong correlation between cellular ATP levels at 120
minutes of reflow and post-ischemic renal function.

Thus ATP levels at 120

minutes of reflow can be used as indicators of the severity of the ischemic
insult.

On the other hand, renal function measurements during reflow are

not good predictors of recovery.

Gaudio et al. (12) found that dopamine,

which enhances renal blood flow, initially improved renal function after 2
hours of reflow, but failed to sustain this improved function 24 hours later.
These investigators noted that at 2 hours of reflow, dopamine had not
significantly changed ATP levels from control values in saline-treated
animals.

Since the initial rapid phase of ATP repletion following ischemia is
dependent on phosphorylation of cellular AMP and ADP, increasing the
TAN levels at the end of the ischemic insult should help ATP regeneration
during reperfusion. Stromski et al. (13) succeeded in increasing the TAN
level at the end of the ischemic interval by administering to rats 2'deoxycoformycin, which blocks the deamination of adenosine to inosine.
Van Waarde et al. (14) obtained similar results by using the ADP analogue
adenosine

a,fi-methylene

diphosphate

dephosphorylation of AMP to adenosine.

(AMPCP),

which

inhibits

the

As predicted, the increase in the

TAN pool size led to a higher recovery of ATP during the initial rapid phase
of ATP regeneration.

Kidney function, as measured by inulin clearance, was

also significantly improved 24 hours after the insult. Interestingly, the rate of
ATP restoration over the ensuing 2 hours was also accelerated.

This is
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probably due to an increase in the endogenous precursors for ATP resynthesis
coupled with a decrease in the amount of cellular and membrane damage.
The reduction in membrane damage may be due to the decrease in purine
base formation which decreases the flow through the enzyme xanthine
oxidase (13), whose activity results in oxygen free radical formation.

These animal experiments support the contention that ATP generated
during the initial rapid phase of recovery is dependent on phosphorylation of
cellular nucleotides.

Furthermore, these studies strongly suggest that

recovery of cellular ATP is rate limiting for the recovery from the ischemic
injury.

The clinical applicability of these observations is unfortunately

limited, because the compounds that were utilized to block AMP degradation
needed to be infused before the ischemic injury was administered.

Manipulations to increase ATP regeneration have also been attempted
during the slow phase of ATP recovery. Siegel et ai. (4) studied the effects of
post-ischemic infusion of an ATP-MgCl2 solution to rats. These investigators
found that whereas the initial rapid phase of ATP regeneration was
unchanged, renal tissue ATP levels at 2 hours of reflow reached 90% of their
pre-ischemic values, compared to only 60% in control animals that did not
receive the ATP-MgCl2 solution (42).

ATP-MgCb infusion has also been

shown to enhance the recovery of renal function (15) and to accelerate the
restoration of injured tubular epithelium (16). ATP-MgCl2 exerts the bulk of
its effects by providing precursors for the resynthesis of cellular adenine
nucleotides (5), which have recently been shown to be taken up by an S-(pnitrobenzyl)-6-thioinosine (NBTI)-sensitive transporter (17).

ATP-MgCl2 is

unlikely to exert its effects via hemodynamic or membrane stabilizing effects
(5), nor is it likely to serve as a direct source of energy (5). Unfortunately, the
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clinical applicability of adenine nucleotide infusions for treatment of ARF are
limited because of their adverse hemodynamic effects.

Surprisingly, Sutter et al. (18) found that ATP regeneration during the
slow phase of ATP recovery is also improved by the post-ischemic infusion of
thyroxin (T4).

Recovery of renal function was significantly accelerated and

was sustained throughout the reflow period.

Repair of damaged tubular

epithelium was also enhanced. In addition to its beneficial effects in ischemia
induced ARF, T4 has also been shown to be effective in accelerating recovery
of glomerular and tubular function in toxic ARF (19,20,21,22).

T4 is believed

to act by enhancing mechanisms of recovery rather than by simply limiting
the severity of the initial insult (18).

Its cellular and molecular mechanisms

of action remain to be determined. They are probably multifactorial, possibly
including the stabilization of cell membranes (by altering their phospholipid
composition, their cholesterol and cardiolipin content, their degree of fatty
acid saturation and their lipid to protein ratio), the stimulation of Na+-K+ATPase and/or of the ADP/ATP translocase (18).

To the best of our

knowledge, there has only been one published report on the clinical use of T4
for the treatment of ARF. Staub (23) reported a prompt diuresis and recovery
of function in eight children with ARF treated with T4.

This study

unfortunately lacked a control group. Nevertheless, its promising results and
the clinical familiarity in using thyroxin, will hopefully generate interest in
future controlled clinical trials that would assess the efficacy of T4 in treating
ARF.
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4) EFFECTS OF ISCHEMIA AND REPERFUSION ON THE MOLECULAR
MECHANISMS OF ATP SYNTHESIS

It should be evident from all the studies cited that ATP regeneration is
rate limiting for renal cellular recovery from an ischemic insult.

Further

insights into understanding the cause(s) of the disrupted and suboptimal ATP
regeneration during reflow may be derived from examining the molecular
mechanisms that underlie ATP synthesis and how they are affected by
ischemia and reperfusion.

ATP is synthesized in the mitochondrial matrix, catalyzed by the
membrane bound enzyme ATP-synthase.

It requires the mitochondrial

uptake of ADP and inorganic Phosphate (Pi).

It is well established that ischemia causes mitochondrial dysfunction.
A specific sequence of mitochondrial morphologic alterations has been
described: Initially, there is condensation of the mitochondrial matrix,
dilatation of the inter-cristae spaces and moderate swelling.

At this stage

these changes are still reversible. Longer durations of ischemia result in large
amplitude swelling, fragmentation of the cristae and formation of flocculent
densities containing proteins and lipids (2).

During the ensuing reperfusion

period calcium phosphate precipitates appear in the matrix and they are seen
as granular densities under electron microscopy (24,25).

These morphologic

alterations are accompanied by mitochondrial functional deterioration. ATP
depletion and acidosis synergistically act to promote this dysfunction (26) via
mechanisms that include loss of intra-mitochondrial adenine nucleotides,
deenergization of the inner mitochondrial membrane, decrease in the
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number and the activity of the nucleotide translocator, activation of
endogenous phospholipases and accumulation or loss of calcium (27).

ADP is taken up by mitochondria in exchange for ATP via a carboxyatractyloside (CAT) sensitive transporter.

We have only identified one

published study that has examined the effects of ischemia and reperfusion on
this exchanger.

Henke and Jung (28) showed that following 60 minutes of

ischemia, the amount of mitochondrial adenine nucleotide translocator
remaining in the inner mitochondrial membrane, which was determined by
titrating state 3 respiration with carboxyatractyloside, was only 55% of that
measured in controls.
assayed.

The activity of this carrier was unfortunately not

Interestingly, quantitative recovery of this exchanger occurred over

several days, suggesting a slow process of resynthesis (28).

Ongoing

experiments in our laboratory are currently examining the immediate effects
of ischemia and reperfusion on the activity of this transporter (Boydstun et
al., personal communication).

Synthesis of ATP also requires the mitochondrial uptake of Pi.

Any

disruption or alteration in this mitochondrial transport process is likely to
adversely affect mitochondrial synthesis of ATP.

The effects of ischemia and

reperfusion on mitochondrial Pi transport have not been previously studied.
We hypothesized that mitochondrial Pi uptake may be decreased during the
ischemic insult and/or during the subsequent reflow period, and that as a
result, the intramitochondrial availability of Pi as a substrate for ATP
synthesis, may become the rate limiting factor in the regeneration of ATP,
which in turn, is the rate limiting step for the renal cellular recovery from an
ischemic insult.
measure

To test these hypotheses, we designed experiments to

proximal

tubular mitochondrial

Pi

uptake

in

ischemic and

reperfused rats.

Proximal tubules were of particular interest as they are the

tubular segment most susceptible to ischemic injury (2), and their ATP levels
during ischemia and reperfusion have been previously well defined and
shown to be similar to those of whole kidneys (93).

5) MITOCHONDRIAL Pi TRANSPORTERS

We herein review the properties of the mitochondrial phosphate
transport processes and the molecular characteristics of the mitochondrial
phosphate transporters.

Phosphate is an essential substrate for cellular growth and replication.
It is a constituent of nucleic acids, membrane lipids and other biomolecules.
It is, therefore, a key component of many cellular and subcellular reactions
including energy metabolism (29).

We are particularly interested in renal

proximal tubular cells, as these are the segment of nephrons that are most
susceptible to ischemic injury (30).

The reabsorption of Pi in proximal

convoluted tubules has been shown to be affected by alterations in the
cytosolic demand for Pi (31), and to be regulated by a multitude of hormonal,
metabolic and dietary factors (for review see reference 32).

Limitation of Pi

availability depletes these cells of many components of oxidative metabolism
including ATP (33).

Not surprisingly, this adversely affects their functional

capacity and their ability to reabsorb fluid (33).

There are several cellular phosphate transporters that have been
described in various tissues (for review see reference 29).

We will limit our

discussion to mitochondrial phosphate transport processes. These were first

identified by mitochondrial swelling experiments (34). Two major phosphate
carriers have since been identified on the inner mitochondrial membrane:

i) The Phosphate Transport Protein (PTP)

The phosphate transport protein (PTP) is a carrier located on the inner
mitochondrial membrane.

Chappell and Crofts (35) first suggested in 1965

that this carrier catalyzes the exchange of inorganic phosphate (Pi) for
hydroxyl anions. This concept was challenged in 1969 by Mitchell and Moyle
(36) who alternatively proposed that this carrier may catalyze the cotransport
of Pi and protons.

In point of fact, these two processes are experimentally

indistinguishable (37) and both lead to acidification on the side to which Pi is
transported.

Proving that one of these proposed mechanisms is the

physiologically correct one will probably require finding appropriate proton
or hydroxyl anion binding regions on the PTP molecule.

Our bias is to

consider this carrier a Pi/H+ cotransporter, since 1) many carrier molecules
that bind and co-transport protons have been described, whereas few hydroxyl
anion carriers are known; and since 2) an abundance of protons is expected to
be found in the intermembrane space (external surface of the PTP) according
to Mitchell's chemiosmotic hypothesis (which proposes that protons are
pumped across the inner mitochondrial membrane as electrons flow through
the respiratory chain).

a-Characteristics of the PTP carrier:

The stoichiometry of this

cotransport is 1:1 as determined by the distribution of Pi in respiration-

1 2

inhibited mitochondria (38).
acid.

Inorganic phosphate is an anion and a weak

The ionic species preferentially transported by the PTP under

physiologic conditions is thought to be the monovalent anion (H2PO4'), even
though at pH=7.4 Pi is present mostly as the divalent anion (HPO4"). This
was concluded from kinetic studies which found that the Michaelis constant.
Km, increases with increasing pH (which increases the fraction of Pi present
in divalent anion form).

Km is defined as the substrate concentration at

which the reaction rate is half maximal, and in practical terms is an inverse
measure of the affinity of the enzyme to its substrate.

In simpler terms, the

PTP has a higher affinity for the monovalent anion of Pi (37).

Freitag and Kadenbach (39) on the other hand challenged this concept,
and conversely suggested that the divalent anion is the ionic species
preferentially transported.

Their conclusions are based on studies that

assayed the transport of various substituted analogues of Pi with different
ionization properties: One of the analogues, a difluorophosphate found only
in monovalent form was not transported, whereas other analogues that were
present in both monovalent and divalent forms were transported.

These

findings should be interpreted with caution, however, as they are based on
mitochondrial swelling experiments, yet control experiments for secondary
effects such as calcium movement and EDTA-induced permeability changes
were not done (40).

The direction of Pi transport is determined by the pH gradient across
the mitochondrial membrane: Alkalinization of the suspending medium
leads to Pi efflux from the mitochondria, and conversely acidification leads to
Pi uptake (41).

More importantly, the activity of the transporter itself is pH dependent.
Compounds that dissipate the pH gradient such as ionophores (which allow
the uptake of protons in exchange for intramitochondrial potassium), block
Pi transport (42).

Similarly uncouplers such as 2,4-dinitrophenol which

partially dissipate the pH gradient, partially inhibit this transport process (42).
This pH dependence is of vital importance, as it allows the PTP to transport Pi
against concentration and electrical potential gradients, by utilizing the
mitochondrial pH gradient as its driving force (29).

It is estimated that as

much as 25% of the protons extruded by the respiratory chain may be used to
support this Pi uptake (29).

The cotransport catalyzed by the PTP is an electro-neutral reaction as
the monovalent Pi (which is the ionic species preferentially transported) is
fully coupled to protons (43,44,45).

The mitochondrial transmembrane

electrical gradient does not significantly influence the affinity and the
maximal transport rate of the PTP.

Changing the membrane gradient or

abolishing it altogether, do not affect the transport of Pi as long as the
transmembrane pH gradient is kept constant (45).

Similarly respiration and ATP hydrolysis do not provide a driving
force, nor do they affect the activity of the PTP.

Indeed a greater than 90%

inhibition of oxidative phosphorylation (achieved by using oligomvcin and
either rotenone or KCN) does not significantly affect Pi transport (46,47).

b-Kinetic parameters of the PTP: The kinetic studies of Pi transport
have greatly been aided by the use of specific inhibitor compounds. Not only
were these inhibitors used to quench time-dependent reactions, but they also

allowed the separate measurement of Pi exchange across the 2 major Pi
transporters (37).

More recently, they proved invaluable in the isolation and

purification of these two carriers (see below).

Two important inhibitors will

be briefly reviewed here: 1) Mersalyl (sodium-X-(3-hydroxymercuri 2methoxypropyl)

carbamoyl-phenoxy

acetate)

is

an

organomercurial

compound that reacts reversibly with the exposed SH-groups of cysteine
residues on proteins (37).

As mercurials are highly polar molecules, mersalyl

can not react with SH-groups residing in apolar environments or within
mitochondria, nor can it penetrate the inner mitochondrial membrane (37).
2) N-ethylmaleimide (NEM) is another inhibitor that reacts with SH-groups
on proteins.

This reaction is dependent on temperature, pH, and the

concentration of maleimide and thiol groups.

In contrast to mersalyl, NEM

reacts irreversibly with the SH-residues, and it does not inhibit Pi transport
across the dicarboxylate carrier (discussed below).
penetrate the inner mitochondrial membrane.

In addition, it is able to

It can therefore act on both

sides of this membrane and in apolar regions of membrane proteins (37).

Early measurements of Pi transport were indirect and were inferred
from studying transport-dependent functions such as ADP stimulation of
respiration (48,49), or from observing the changes in light scattering due to
ammonium

phosphate

induced

mitochondrial

swelling

(50).

Direct

measurements of Pi transport became possible in 1974 when Coty and
Pedersen (42) introduced an inhibitor-stop technique (described in the
Methods section) that exploited the characteristic inhibition patterns of the Pi
carriers. Their results were corroborated by Ligeti et al. (45) who measured Pi
transport in a similar manner with the exception that the transport process

was stopped by cessation of substrate supply, not by addition of specific
inhibitors.

Pi transport was found to be a typical carrier-mediated process
exhibiting saturation kinetics.

Utilizing indirect methods of Pi transport

measurement, Fonyo et al. (51) found this transport process to have a low
affinity for Pi at room temperature (Km =1.95 mM) .

Similarly,

both Coty

and Pedersen (42) at 0°C and Ligeti et al. (45) at room temperature obtained a
Km of 1.60mM with direct methods.

As previously mentioned. Km

decreased with increasing acidity.

The specific activity (Vmax) of this transport process has also been
measured.

At 0°C, Coty and Pedersen (42) described a Vmax of 205 nmol

Pi/min/mg mitochondrial protein. At 22°C, Ligeti et al. (45) found this Vmax
to be 3000 nmol Pi/min/mg mitochondrial protein. This rate is two orders of
magnitude

higher

than

that

for

adenine

nucleotide

transport

(2-7

nmoles/min/mg at 0°C) (52). It is also significantly greater than the overall
rate of oxidative phosphorylation: The maximal rates of ATP production
observed in liver mitochondria respiring with pyruvate and succinate are 400
nmol of ATP/min/mg mitochondrial protein at 10°C (53) and 1000 nmol of
ATP/min/mg mitochondrial protein at 25°C (54).

The uptake of Pi in such large quantities suggests that Pi may have
important mitochondrial functions besides serving as substrate for ATP
synthesis. These functions are discussed in detail below.

A more accurate determination of the activity of a carrier is its
turnover number, which is defined as the number of substrate molecules that
are transported by the enzyme per unit time, when this enzyme is fully

saturated with substrate.

In essence, the turnover number measures the

specific activity of a single carrier molecule.

It is obtained by dividing the

specific activity of the carrier by its concentration.

The amount of PTP in rat

liver mitochondria has been estimated to be 50-60 pmol/mg mitochondrial
protein by Coty and Pedersen (55), Hadavry and Kadenbach (56) and Fonyo
and

Vignais

(57)

in three separate studies that used

experimental procedures.

three

different

The calculated turnover number in rat liver

mitochondria therefore ranges from 3500 min*1 at 0°C (55) to 50,000-60,000
min*1 at 20-25°C (45).

These numbers have recently been questioned by

Wohlrab (58,59) who calculated a minimum turnover number of 2000-7000
min*1 at 22°C in reconstituted proteoliposomes containing purified beef heart
protein. This order of magnitude difference suggests that either the estimated
amount of PTP in intact mitochondria or the purity and functional integrity
of the isolated protein need to be re-evaluated (45).

Nevertheless,

these

values

are

higher

than

the

corresponding

turnover numbers of other membrane transport systems studied in detail,
such as the mitochondrial adenine nucleotide carrier (500 min*1 and 600 min'
1

at 18°C in bovine heart and rat liver mitochondria respectively) (60), the

lactose permease of E. coli (2900 min*1 at 25°C) (61), the brush border
membrane Na+-glucose transporter (1200 min*1 at 20°C) (62), the chloroplast
membrane Pi carrier (5000 min*1 at 20°C) (45) and the sarcoplasmic reticulum
Ca-ATPase (4400-16700 min'1) (63). In contrast to these, the band 3 protein of
erythrocytes which is responsible for CP/HCO3" exchange has a much higher
turnover number (50,000 s'1 at 38°C) (64).

c-Molecular studies of the PTP: The unequivocal determination that
these kinetic parameters are specific to the PTP itself required that this protein
be isolated, purified and its activity reconstituted in liposomes.
tedious process is comprehensively reviewed in reference 34).

(This very

The isolation

of this carrier was aided by its irreversible binding to N-ethylmaleimide.
Unfortunately, this inhibitor reacts covalently with the SH-groups of many
mitochondrial matrix and inner membrane proteins whose molecular
weights are similar to that of PTP (~34 Kd), making their separation by gel
electropheresis very difficult, and necessitating that many procedures be
designed to increase the specificity of N-ethylmaleimide towards the SHgroups of PTP. The purification steps also had to be delicately refined as the
contaminant proteins turned out to have chemical properties similar to those
of PTP.

Optimal purification required the use of 1) sodium dodecylsulfate

(SDS) to remove bound lipid or to unfold the protein, and 2) a carefully
chosen hydroxylapatite ionic exchange chromatographic medium.

It was not

until 1984 that Kolbe et al. (65) succeeded in purifying the PTP from beef heart
mitochondria to homogeneity.

Interestingly, the 2 major contaminant

proteins sharing similar size and chemical properties with PTP were
identified as the Pi/dicarboxylate exchanger and the ADP/ATP translocator,
two mitochondrial carrier proteins functionally related to PTP.

To date, PTP has been isolated and purified from the mitochondria of
bovine heart (58,66), porcine heart (67), rat liver (68), rat heart (34), blowfly
flight muscle (59), and the fungi Sacchnromyces
parapsilosis (69).

cerivisiae and Candida

These purified proteins have been incorporated into

liposomes using a modification of the freeze-thaw-sonication method

developed by Kasahara and Hinkle (70).

This has allowed the reconstitution

of the activity of the PTP in vitro.

The biochemical properties and kinetic parameters of the reconstituted
PTP turned out to be similar to the ones reported above (34).

This confirms

the validity of both Coty and Pedersen's inhibitor-stop technique and Ligeti et
al.'s rapid filtration technique for measurement of Pi transport across the
PTP.

More importantly, the reconstitution of PTP in a catalytically active

form should help elucidate the molecular characteristics of Pi transport across
this carrier. Studies are currently under way (34) to determine whether PTP is
active as a monomer or a dimer, and whether it is sensitive to autoxidation
(59,67).

Its

topology,

structural

and

functional

mitochondrial membrane are being investigated (34).

asymmetry

in

the

Furthermore, the

molecular structure and the catalytically active sites of the protein are being
delineated (see below).

Since PTP is the only transport protein other than bacteriorhodopsin
(72) that has been rigorously identified, highly purified (65) and its activity
reconstituted into liposomes (73), understanding the molecular mechanisms
of Pi transport across the mitochondrial membrane as well as the role of
individual amino acids in this transport process will greatly contribute to our
understanding of membrane transport processes in general.

In this respect,

studying the effects of ischemia and reperfusion on mitochondrial Pi
transport may provide important information about mitochondrial transport
processes in general.

The isolation, purification and reconstitution of the activity of the PTP
has been complemented by the recent sequencing of the amino acid

composition of the bovine heart PTP (65).

This amino acid sequence was

deduced from the nucleotide sequence of several

overlapping clones

encoding for this carrier protein (74). A full length cDNA clone encoding the
precursor of the rat liver mitochondria PTP has also been isolated, sequenced,
characterized and its amino acid composition deduced (75).

The bovine heart (MW 34,740) and the rat liver mitochondrial Pi
carriers contain 312 and 313 amino acid residues respectively.

Even though

their kinetic parameters are identical, they differ in 32 amino acids (~10%).
They show considerable more variability than the P-subunit of the ATP
synthase enzyme, in which only 5 out of 480 residues differ between the rat
liver and the beef heart enzymes (29).

It therefore appears that more amino

acid changes are tolerated by the Pi transport proteins than by the fi-subunit of
ATP synthases.

The significance of these changes in these two crucial

proteins involved in oxidative phosphorylation remains unclear (75).

In addition to differences among species, there appear to be physical
(although not functional) differences in PTP among organs of the same
species.

Indeed, the Pi transport proteins from rat heart and rat liver show

differences in their mobilities, their cyanogen bromide-generated peptide
maps and in the Western blots of their cyanogen peptides (34).

It is not

known whether these differences are due to alternate mRNA splicing,
posttranslational processing, multiple genes or a combination of these (34).

Comparing the amino acid sequence of PTP with those of other known
proteins such as Pi binding proteins, H+-linked symporters and the human
glucose transporter does not reveal any significant homologies (75).

In

contrast to many bacterial transporters (E. coli lactose permease, xylose/H+
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symporter and melibiose carrier) and to the human erythrocyte glucose
symporter which all have 12 transmembrane segments, the hydropathy
profile of the rat liver mitochondrial PTP suggests the presence of only 6
transmembrane segments per molecule (75), with hydrophobic residues
comprising

59%

of

the

total

protein

(which

is

appropriate

for

a

transmembrane protein) (29). If the biologically active form of the PTP turns
out to be a dimer, which is the case for the ADP/ATP translocator (76), then
the Pi carrier would functionally have 12 trans-membrane segments (75).
Understanding the topology and molecular mechanisms of the Pi transporter
may help clarify the structural and functional significance of this common
motif that is found in many prokaryotic and eukaryotic carrier molecules.

With the availability of the amino acid sequence of the PTP, studies to
determine the site(s) of action of inhibitors were undertaken. Only one of the
eight cysteine residues found in the bovine heart mitochondrial PTP was
found to react with N-ethylmaleimide (29).

This reactive cysteine is present

on the external surface of the membrane at position 42 and is flanked by
positive charges (Lysine 41 and Arginine 43) which are thought to stabilize
the reactive thiolate anion (78).

Ligeti and Fonyo (77) found the reactivity of

this cysteine 42 thiol group to be affected by alterations in both the external
pH and the intramitochondrial pH.

Since cysteine 42 is present on the

external surface of the membrane, they speculated that the effects of
intramitochondrial

pH

changes

are

probably

transmitted

transmembrane steric or conformational alterations.

through

The reactivity of

cysteine 42 was not influenced by substrate concentrations, suggesting that the
amino acid residues around the NEM-reactive cysteine do not participate
directly in substrate binding (77).

Rather, Ligeti and Fonyo speculated that
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this region may play a permissive role in Pi transport: In its free state it would
allow the PTP molecule to undergo a conformational change that would be
required for Pi transport; in its blocked state, as when bound to Nethylmaleimide,

it

would

prevent

the

PTP

from

undergoing

this

conformational change by sterically interfering with its molecular motion
(77).

Recently, Phelps et al. (79) cloned and sequenced the PTP gene from the
yeast Saccharomyces cerivisiae.

The DNA sequence has an overall sequence

homology of 38% to the bovine heart protein (80), with 33% fewer basic and
acidic amino acids.

The 2073 bases of clone code for 311 amino acids (MW

32,814) with a hydropathy profile suggestive of 6 transmembrane segments.
Interestingly, these hydrophobic segments contain most of the conserved
amino acids.

The kinetic parameters of this yeast PTP are similar to those of

the beef heart protein (79).

Compared to the PTP from beef heart, the yeast carrier retained its high
sensitivity

towards

ethylmaleimide (79).

mersalyl,

but

lost

its

sensitivity

towards

N-

Guerin et al. (69) found that this yeast protein lacks the

reactive cysteine 42 residue of the beef heart carrier. This supports Ligeti and
Fonyo's conclusion that cysteine 42 does not participate directly in Pi binding.
Interestingly, Phelps and Wohlrab (80) succeeded in making this yeast carrier
sensitive to N-ethylmaleimide by using site-directed mutagenesis that
replaced threonine at position 43 with a cysteine residue. Since the yeast PTP
which lacks cysteine 42 retains its sensitivity to mersalyl, this inhibitor must
react with some other SH group in the protein (69).

It is hoped that site-

directed mutagenesis will help identify this group and better characterize the
relationship of various SH groups to the function of the PTP.
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PTP has been grouped into a family of mitochondrial anion transport
proteins (29) that include the ADP/ATP exchanger and the uncoupling
protein

from

brown

fat

mitochondria.

These

three

proteins

have

significantly homologous primary structures including an internal three-fold
structural repeat (29).

In addition, they all have 6 membrane spanning

hydrophobic segments, comparable molecular masses (30-34 Kd) and behave
similarly during purification (80). They are probably encoded in nuclear, not
mitochondrial DNA, as the N-terminal amino acid sequence of the bovine
heart PTP fails to match any region of the bovine heart mitochondrial DNA
(65,78).

Analysis of the biosynthesis of PTP uncovered a 49-residue leader
sequence.

This sequence is important in protein targetting, and is cleaved

after the protein is embedded in the mitochondrial membrane (74).

This

presequence is not found in the ADP/ATP exchanger or the uncoupling
protein from brown fat mitochondria.

Analysis of their import into

mitochondria by deletion mutagenesis revealed that the information needed
to direct these proteins to mitochondria resides within different segments of
the proteins themselves (81).

These three carriers are believed to have

evolved from a common ancestral gene by gene duplication of an internal
repeat corresponding to 100 aa (81).

Unlike the other two transporters, the

PTP is present in prokaryotes, and is therefore believed to be the oldest
member of the family.
early

targetting

The leader sequence of the PTP likely represents an

mechanism

that

was

eliminated

evolutionary development of the other two carriers (81).

in

the

subsequent
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ii) The Pi/dicarboxylate exchanger

In

contrast

Pi/dicarboxylate

to

the

exchanger

phosphate
which

is

transport
the

other

protein
major

(PTP),

the

mitochondrial

phosphate transporter has not been as extensively investigated.

Evidence for

the presence of an independent Pi carrier separate from the PTP was first
presented by Chappell and Crofts in 1966 (50).

They showed differences in

sensitivities to Pi transport inhibitors and differences in rates of Pi uptake
when exchanging Pi for hydroxyl anions versus dicarboxylates.

Since that

time most investigators have supported this concept, although some authors
have argued for the existence of a single Pi carrier whose transport properties
are modified upon binding certain inhibitors such as n-butylmalonate or Nethylmaleimide (82).

The isolation of PTP and reconstitution of its activity

into liposomes provided new evidence that strongly supported the existence
of

two

separate

proteins:

The

reconstituted

PTP

retained

its

N-

ethylmaleimide sensitivity, kinetic characteristics and catalytic properties,
while remaining insensitive to n-butylmalonate (66).

a-Characteristics of the Pi/dicarboxylate exchanger: Unlike the PTP,
which catalyzes the transport of the monovalent Pi anion, the distribution of
Pi in respiration inhibited mitochondria suggests that it is the divalent anion
(HPO4") that is transported across the Pi/dicarboxylate exchanger (38). Pi is
transported in exchange for the respiratory substrates malate, malonate or
succinate.

The reaction is electroneutral.

In addition to catalyzing the

exchange of Pi for dicarboxylates, the Pi/dicarboxylate carrier can catalyze the
exchange of Pi to Pi and of dicarboxylates to dicarboxylates.

This carrier

probably has different binding sites for Pi and dicarboxylates (83) as kinetic
studies have shown an order of magnitude difference between the Km values
for dicarboxylates and Pi (0.2 and 1.5 mM respectively) (83). In contrast to the
PTP which has a high substrate specificity, the dicarboxylate carrier can
additionally bind sulfates, sulfites and thiosulfates (34).

The driving force for dicarboxylate exchange with Pi is the inner
mitochondrial membrane Pi gradient (43).

This in turn is established at the

expense of the membrane pH gradient via the PTP.

Thus the mitochondrial

dicarboxylate uptake via the Pi/dicarboxylate carrier is indirectly coupled to
the

inner

mitochondrial

membrane

pH

gradient

(42).

Furthermore,

dicarboxylates have been shown to be transported in exchange for other
mitochondrial substrates such as citrate (83) and a-keto glutarate (83). Hence
the

mitochondrial

uptake of these substrates is

also coupled

to

the

transmembrane pH gradient, and it is dependent on the establishment of
appropriate Pi and dicarboxylate transmembrane gradients via the concerted
activities of the PTP and the Pi/dicarboxylate exchanger (55).

b-Kinetic

parameters

of

the

Pi/dicarboxylate

exchanger: The

Pi/dicarboxylate exchanger is competitively inhibited by the substrate
analogues n-butylmalonate and phenvlsuccinate (55) which are substituted
dicarboxylic acids that have no effect on the PTP.

The Pi/dicarboxylate

exchanger is sensitive to mersalyl only at high doses, but is insensitive to Nethylmaleimide (34).

Exploiting these characteristic inhibitor sensitivities,

Coty and Pedersen (42) measured the kinetic parameters of this carrier using
their inhibitor-stop technique.

They found the Km at 0°C to be 1.76mM,

which is experimentally indistinguishable from the Km of PTP (1.6 + 0.19
mM).

On the other hand, Vmax of the dicarboxylate carrier was 15 nmol

Pi/min/mg mitochondrial protein which is significantly lower than that of
the

PTP

(205

nmol

Pi/min/mg

mitochondrial

protein).

At

room

temperature, Wohlrab found Vmax to be 70 nmol Pi/min/mg mitochondrial
protein (34).

c-Molecular

studies

of

the

Pi/dicarboxylate

exchanger:

dicarboxylate carrier has not been purified to homogeneity yet.

The

The best

purification obtained from a dicarboxylate transport-active preparation
contains at least six to nine distinct protein bands on SDS-PAGE, with a
mobility in the vicinity of 30Kd (84).

Recently, Saint-Macary and Foucher

succeeded in incorporating the dicarboxylate exchanger from a detergent
solubilized rat liver mitochondrial fraction into liposomes (85).

This

exchanger closely resembled the PTP in its behavior during purification, and
its reconstitution into liposomes similarly required cardiolipin for optimal
activity (29).

To date, no Pi transport activity has been successfully

reconstituted (29) but a dicarboxylate-dicarboxylate exchange activity has been
achieved (85).

This reconstituted exchange

is sensitive to n-butylmalonate

and mercurials, but not to N-ethylmaleimide (85).

In a separate series of

experiments, Kaplan and Pedersen succeeded in reconstituting malate self¬
exchange activity from Pi/dicarboxylate exchangers incorporated into
liposomes via the freeze-thaw-sonication method (84).

Unfortunately, their

calculated exchange rate at room temperature differed 45-fold from the one
reported by Saint-Macary and Foucher.

This discrepancy may be due to the

fact that these exchange rates were calculated per unit amount of protein, yet
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their protein determinations were unreliable because of the presence of high
concentrations of lipids and detergents (34).

The membrane concentration and turnover number of this carrier
have not been determined yet.

These would help explain whether the low

dicarboxylate transport capacity of the rat liver mitochondria is due to a low
concentration of transport protein(s) that have a high turnover number or to
a high concentration of protein(s) that have a low turnover number (34).

iii) Other Mitochondrial Pi transporters

The PTP and the Pi/dicarboxylate exchanger are the best characterized
mitochondrial Pi transporters, and they probably account for most of this
transport.

Other mitochondrial Pi carriers have also been reported, but

neither their kinetic parameters nor the extent of their contribution to Pi
transport are known.

Aprille et al. (86) have described an ATP-Mg/Pi exchanger in rat liver
mitochondria.

The transported Pi species is the divalent anion.

This

transporter is insensitive to carboxyatractyloside, but is inhibited by relatively
high concentrations of mersalyl or N-ethylmaleimide.

It has no activity at

4°C, but it is stimulated by sub-micromolar (0.2-0.8|iM) concentrations of
calcium.

The direction of flow is dependent on the energy status of the cell

(ie the ATP/ADP ratios in mitochondria and in the cytoplasm).

This ATP-

Mg/Pi exchanger alters the absolute concentrations of ATP, ADP and AMP
without changing the matrix ATP/ADP ratio.

It is therefore believed to

function in regulating the mitochondrial matrix TAN pool size.

This in turn
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selectively regulates those metabolic activities localized to the mitochondrial
compartment that have adenine nucleotide dependent steps
synthesis,

gluconeogenesis,

mitochondrial

biogenesis,

(eg urea
oxidative

phosphorylation etc.) (86).

Toninello

et al. (87) have postulated the existence of a liver

mitochondrial Pi efflux mechanism that is separate from that of Pi influx.
Through inhibitor sensitivity experiments, they showed that whereas
mitochondrial Pi uptake was blocked by mersalyl and N-ethylmaleimide in
the presence or absence of spermine, the inhibition of Pi efflux by both
mersalyl
spermine.

and

N-ethylmaleimide

was

almost

completely

reversed

by

Therefore, they concluded that the pathway for Pi efflux was

distinct from that for Pi uptake.

Unfortunately, their results are difficult to

interpret because they did not control for the activity of the Pi/dicarboxylate
exchanger nor did they examine the effects of spermine on this carrier which
is known to extrude mitochondrial Pi.

Recently, Kikuchi et al. (88) have characterized an ATP dependent
mechanism for Pi uptake in rat intestinal mitochondria that is sensitive to
the mercurial agent p-chloromercuribenzoic acid (p-MB).

Their experimental

design, however, does not preclude PTP from being the active carrier in these
investigations.

Interestingly, they showed

that

this

ATP dependent

mechanism for Pi uptake was regulated by l,25-(OH)2 vitamin D3.

Finally, recent experiments (89,90) have disproved a previously
proposed mitochondrial Pi efflux pathway via an atractyloside sensitive
(2ATP/2ADP,Pi) exchanger (91). Instead, Kaplan and Pedersen found Pi efflux
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to occur via the PTP and via a mersalyl-insensitive saturable process that may
represent a new yet undefined carrier (90).

6) IMPORTANCE OF MITOCHONDRIAL Pi TRANSPORT

In this detailed review of mitochondrial Pi transport processes, it
becomes evident that inorganic phosphate and Pi transport must have many
important

mitochondrial

functions

besides

supplying

an

elementary

substrate for oxidative phosphorylation.

By the sequential action of the PTP, the Pi/dicarboxylate,

the

dicarboxylate/tricarboxylate and the 2-oxyglutarate carriers. Pi couples the
mitochondrial transport of various citric acid intermediates (such as malate,
malonate, succinate, citrate and a-ketoglutarate) to the membrane pH and
controls their distribution between mitochondria and cytoplasm (37).

Moreover, Pi within the matrix serves as proton-donor for the proton
pump of the respiratory chain, while Pi transport maintains proton flow (37).
The modulation and regulation of mitochondrial divalent cation transport is
dependent upon the co-transport of proton-donating anions such as Pi (42).

Ligeti et al. (45) speculate that the pH dependent transport of Pi on the
PTP may function to rapidly equilibrate changes in the transmembrane pH
gradient, thereby maintaining the proton electrochemical gradient almost
completely in the form of membrane potential.

From an evolutionary perspective proper Pi transport across the
mitochondrial membrane is absolutely essential for life in obligatory aerobic
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eukaryotic cells. Mutations that damaged the Pi carriers (especially the PTP)
had to be lethal. These mutations could only occur in eukaryotic cells capable
of surviving on ATP synthesized in the cytoplasm (eg yeasts and molds) (37).
McGivan et al. (92) demonstrated that inhibiting Pi transport blocked
phosphorylation of extra-mitochondrial ADP even when sufficient Pi was
present inside the mitochondria.

Whereas the ADP/ATP exchange was

inhibited, the ADP/ADP exchange was not affected. They concluded that Pi
transport may act to neutralize the charge imbalance that results from the
mitochondrial exchange of ADP3_/ATP4' during oxidative phosphorylation.
The mitochondrial transport of adenine nucleotides and Pi would therefore
be indirectly coupled by the requirement for charge compensation.

In our

opinion, these conclusions need to be revisited in light of the fact that Pi
transport across the 2 major mitochondrial Pi carriers has been shown to be
electroneutral.

7) SUMMARY
In summary, ARF is an important entity with poor clinical outcome.
Effective therapeutic measures are lacking.

A better understanding of the

pathophysiologic mechanisms underlying the injury and recovery processes
may provide important insights for designing novel therapeutic options.
In a rat model that mimics ischemia induced ARF, renal cellular ATP
is significantly decreased during ischemia.
recovery of ATP follows a biphasic pattern.

During subsequent reperfusion,
An initial rapid phase returns

ATP levels to 50% of pre-ischemic values within 15 minutes.

This is
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followed by a slower phase that returns ATP to 60% of pre-ischemic values
after 2 hours of reflow.

In the rapid phase, ATP is generated from the

phosphorylation of ADP and AMP, whereas in the slower phase, it is re¬
synthesized de novo.

ATP regeneration is one of the rate limiting steps in the recovery from
the ischemic injury.

Manipulations that increase ATP improve the recovery

of renal function.

ATP is synthesized in the mitochondrial matrix and requires the
uptake of the precursor substrates Pi and ADP.

Any disruption in these

mitochondrial transport processes is likely to adversely affect the synthesis of
ATP.

In particular, the effects of ischemia and reperfusion on mitochondrial

Pi transport have not been previously studied.

We hypothesized that

mitochondrial Pi uptake may be decreased during the ischemic insult and/or
during

the

subsequent

reflow

period,

and

that

as

a

result,

the

intramitochondrial availability of Pi may become the rate limiting factor in
the regeneration of ATP.

To test these hypotheses, we designed experiments

to measure proximal tubuler mitochondrial Pi uptake in ischemic and
reperfused rats.

METHODS

1) PREPARATION

OF MITOCHONDRIA

FROM

RENAL

CORTICAL

SUSPENSIONS ENRICHED IN PROXIMAL TUBULES

a-Renal Ischemia: Adult male Sprague-Dawley rats weighing 200-250g
were obtained from Camm (Wayne, NJ) and fed a regular diet. On the day of
study, animals were anesthetized with Inactin (100 mg Inactin/kg body
weight) IP.

Rats were placed on a heated board and their temperature was

kept at 36-37.5°C rectally. A tracheotomy was performed to secure the airway
and aspirate excess lung secretions.

The right internal jugular vein was

isolated and cannulated with a PE-50 polyethylene catheter.
was infused at maintenance rates (1.2ml/hour).

Normal saline

A midline abdominal

incision was performed and the retroperitoneal area was exposed.

The

abdominal aorta, and both the right and the left renal arteries were isolated.

Rats were divided into control and experimental groups.

In the

control group, animals were sham operated but were not subjected to an
ischemic insult.

In the experimental group, renal ischemia was produced in

the following manner: Heparin (500 units/kg) was infused through the
internal jugular vein and allowed to circulate for 10 minutes.

A vascular

bulldog clamp was then placed for 45 minutes on the aorta proximal to the
origins of the renal arteries.

At the end of this ischemic interval, the aorta

was undamped and the kidneys were allowed to reperfuse for 0 or 30
minutes.

b-Procedure for harvesting proximal tubules:

Gaudio et al.'s (93)

modification of the procedure described by Balaban and Mandel (94) was used.
The aorta was first carefully cannulated with PE-90 tubing just distal to the
origins of the renal arteries.

Then the aorta was tied at 2 sites, one proximal

to the origins of the renal arteries, and the other distal to the catheter but
proximal to the origin of the inferior mesenteric artery.

To insure that

solutions infused through the aortic catheter would only perfuse the kidneys,
the superior mesenteric artery was clamped indirectly by tying several loops
of proximal small bowel.

The left renal vein was incised and the kidneys were rapidly flushed
with 10-15cc of a buffered Ringer's solution that had been equilibrated with
95%C>2 / 5%CC>2 at 37°C.

Ringer's Solution contained 112mM NaCl, 3mM

KC1, ImM K2HP04, 1.2mM MgS04/ 25mM NaHC03, 1.5mM CaCl2 and the
metabolic substrates Na-Lactate 4mM, glucose 5.5mM, L-alanine 6mM and
Na-butyrate ImM.

The pH was adjusted to 7.4.

Unless otherwise indicated,

the solution was kept on ice and bubbled with 95%02 / 5%C02- Then 65cc of
a warmed (45°C) and buffered Ringer's solution that contained 110 mg of
collagenase and 10 mg of protease was infused at a rate of 3cc/minute.

The

digestion was stopped by flushing the kidneys with lOcc of an ice cold buffered
Ringer's solution.

The kidneys were then excised and placed in an ice-cold buffered
Ringer's solution.

All the subsequent harvest procedures were performed on

ice and all the suspensions were equilibrated with 95%C>2 / 5%C02-

The

capsules were carefully peeled off and the corteces were gently scraped with
razor blades. The scraped cortical material was suspended in 25cc of buffered
Ringer's solution, stirred for 15 minutes and then filtered through three

layers of gauze.

This process was performed twice.

The filtrate, now an

enriched suspension of proximal tubules, was washed and allowed to
sediment by gravity.

An aliquot of the sediment was examined under light

microscopy to confirm the predominance of proximal tubules based on their
distinct histomorphologic characteristics.

c-Preparation of mitochondria:
kept on ice.

All solutions and suspensions were

The renal cortical suspensions containing proximal tubules from

2 rats (4 kidneys) were pooled and allowed to sediment by gravity.

The

supernatant Ringer's solution was decanted and the proximal tubules were
resuspended in an ice cold mitochondrial isolation buffer (220mM mannitol,
70mM sucrose, 2mM HEPES, ImM EDTA, 0.5mg/ml defatted Bovine Serum
Albumin (BSA), pH=7.4).

The suspension was then homogenized in a 15ml

glass homogenizer vessel with the use of an overhead stirrer (Wheaton).
The homogenate was centrifuged using a fixed-angle rotor (Sorvall RC-5B
Refrigerated Superspeed Centrifuge) at 1,000 g for 10 minutes at 4°C.

The

supernatant was collected and centrifuged at 10,000 g for 10 minutes at 4°C.
The resultant mitochondrial pellet was resuspended in an appropriate
amount of isolation buffer to obtain a final protein concentration of 1-2
mg/ml, and kept on ice.

2) MITOCHONDRIAL PHOSPHATE TRANSPORT ASSAY

Mitochondrial Pi transport was assayed according to Carpenter and
Shiratori's (95) modification of Coty and Pedersen's rapid inhibitor-stop
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technique (96).

All solutions were kept on ice throughout the procedure,

lml of the mitochondrial suspension was mixed with a

solution of

unlabelled inorganic phosphate (Pi) (KH2PO4) to a final Pi concentration of
5mM.

The mixture was diluted with isolation buffer to a final volume of

2ml and was stirred for 15 minutes to allow the Pi to equilibrate across the
mitochondrial membrane.

Then at time t=0, approximately 40pCi of

radiolabelled KH2[32P]C>4 (Dupont-New England Nuclear, Boston) were added
to the suspension.

This radioactive Pi had been boiled for three hours in the

presence of 0.1N HC1 (to de-polymerize any phosphate complexes that may
have formed) and then neutralized with 0.1N KOH just prior to its use.

Immediately upon addition of the radioactive Pi, serial 200|il aliquots
of the mitochondrial suspension were sequentially pipetted at specified time
intervals into separate vials.

Each vial contained 1.8ml of a rapidly stirring

inhibitor solution containing isolation buffer and the two mitochondrial Pi
transport inhibitors mersalyl (0.08mM) and n-butylmalonate (0.25mM).

An

electrical switch device that connected the pipette to a chart recorder allowed
the accurate documentation of the exact sampling time of each pipetted
aliquot.

Each pipetted aliquot was stirred for 2 minutes with the inhibitor
solution and then transferred from the vial to a centrifuge tube. The vial was
washed with 4ml of isolation buffer to collect any remaining mitochondria,
and this buffer was added to the corresponding centrifuge tube.

Each

inhibited mitochondrial solution was centrifuged at 10,000 g for 15 minutes at
4°C.

The supernatant was decanted and saved for determination of its

radioactive counts.

The mitochondrial pellet was washed with 4ml of

isolation buffer and centrifuged again at 10,000 g for 15 minutes at 4°C. The

supernatant was discarded and the centrifuge tubes were inverted to decant
any remaining buffer.

The mitochondrial pellet was air dried for 15 minutes

then resuspended in 1ml of

88%

formic acid.

For each mitochondrial preparation an additional control experiment
was concomitantly performed.

The procedure was similar to the one just

described except that the two inhibitors mersalyl and n-butylmalonate were
added to the initial mitochondrial suspension 3 minutes prior to the addition
of the radioactive Pi.

Pre-incubating the mitochondria with mitochondrial Pi

transport inhibitors allowed the determination of the amount of non-specific
background Pi binding to mitochondria.

For each pipetted mitochondrial aliquot, the radioactive counts of the
inhibited mitochondrial suspension and the corresponding supernatant
solution were determined by adding 0.4ml of solution to 5ml of Ecoscint
(National Diagnostics) scintillation fluid and placing the mixture in a liquid
scintillation analyzer (TRI-CARB 1600 CA).

3) PROTEIN ASSAY

Protein estimations were determined according to Lowry et al.'s (97)
protein

assay

method.

All

manipulations

were

performed

at room

temperature on the same day the mitochondria were prepared.

Albumin

standard controls and the original mitochondrial suspension were diluted to
200pl with distilled water.

Each sample was mixed with 2ml of a copper

alkaline reagent (consisting of

1

volume of a

10%

K-Tartarate solution, 1 volume of 0.8N NaOH,

NaC03,
1

0.1%

CUSO4,

0.2%

volume 10% SDS and 5
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volumes of water).

10 minutes later, 400gl of 0.5N Folin-Ciocalteu phenol

reagent was added to each mixture. Absorbance readings were performed 30
minutes later in a spectrophotometer (Pharmacia LKB - Novaspec II) at a
wavelength of 750nm.

A standard curve was constructed from the

absorbance values of the albumin standards, and the protein concentration of
the mitochondrial suspension was determined from linear regression
analysis.

4) CALCULATIONS

For each aliquot of the mitochondrial suspension that was added to the
inhibitor solution at time t, the amount of Pi taken up per unit amount of
mitochondrial protein was calculated in the following manner: The ratio of
unlabelled intramitochondrial Pi to unlabelled Pi in the suspension is equal
to the ratio of the total radioactive counts in the mitochondrial pellet to the
total radioactive counts in the collected supernatant.
proportional to the ratio of the measured

This latter ratio is

radioactive

counts

in

the

mitochondrial pellet (Mr) to the measured radioactive counts in the collected
supernatant (Sr). The proportionality factor is 1/6 since the volume in which
the mitochondrial pellet was resuspended was 1 /6th the volume of the
collected supernatant.

The following assumptions regarding mitochondrial Pi transport were
made: 1) the rate of mitochondrial Pi transport is equal to the rate of
radiolabelled Pi transport at equilibrium; 2) the net amount of Pi taken up by
mitochondria and 3) the amount of tracer radiolabelled Pi added are both
negligible compared to the initial amount of unlabelled Pi (10 pmoles).

This

initial unlabelled Pi (Ip) could thus be used as a measure of the unlabelled Pi
in the suspension at the end of the transport assay.

Hence, the formula to calculate the amount of Pi taken up by
mitochondria per mg mitochondrial protein could be written as
Mr x Ip

6 x Sr x Co
where Mr is the measured radioactive counts in the mitochondrial pellet, Ip
is the initial amount of unlabelled Pi added, Sr is the measured radioactive
counts in the collected supernatant and Co is the protein concentration of the
initial mitochondrial suspension.

The units of this formula are nmoles of

Pi/mg mitochondrial protein.

This formula is applicable to calculating the amount of unlabelled Pi
taken up by mitochondria only after the transport of radiolabelled Pi has
reached a steady state (see the Results section for an explanation).

For each

mitochondrial preparation, the calculated values of Pi uptake were averaged
to give the mean amount of Pi taken up by mitochondria (Tm).

This value

was corrected for non-specific background Pi binding by substracting the Tm
of the corresponding control experiment.

5) STATISTICAL ANALYSIS

All data are reported as means + SD. One-way analysis of variance tests
was performed. Post hoc contrast tests by the least-square method were used
to determine significant factors.

These procedures were performed with a
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Systat statistical software package (Evanston, IL) on an Epson Equity 11+
desktop computer.

RESULTS

The effects of ischemia and reperfusion on mitochondrial Pi transport
have not been previously investigated.

Rat renal proximal tubules were

harvested from 2 rats (4 kidneys) by a procedure that has been well validated
(93).

Mitochondria from these proximal tubules were prepared according to

standard techniques.

In each preparation, an aliquot was used for the

standard Pi transport assay, a second aliquot was used for the control assay,
and a third was used for determining the protein concentration.

Mitochondrial Pi transport was assayed by a rapid inhibitor-stop
technique.

The assay was performed at 0°C because the temperature-

dependent mitochondrial Pi transport is sufficiently slow at this temperature
so that when the mitochondrial samples are pipetted into the inhibitor
containing vials, the time of mixing and inhibition becomes small compared
to the sampling time (42).

For each experiment. Pi transport was determined throughout a timecourse. Figure 1 shows the results of these assays from a single mitochondrial
preparation from a control rat.

The upper curve represents the standard

assay, whereas the lower curve represents the accompanying control assay to
establish background binding, in which the mitochondria were pre-incubated
with

the

2

mitochondrial

Pi

transport

inhibitors

butylmalonate prior to the addition of the tracer Pi.

mersalyl

and

n-
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In the standard assay, mitochondrial accumulation of radiolabelled Pi
can theoretically be extrapolated to an initial value of 0.

This accumulation

then rapidly increases, reaching a steady state within 5-10 seconds.

Steady

state indicates that transport of the tracer Pi has achieved equilibrium (but is
not indicative of any change in the activity of the mitochondrial phosphate
transporters which remained at equilibrium throughout the experiment).
This initial rapid phase of radiolabelled Pi uptake therefore measures the
rapidity with which tracer Pi achieves equilibrium across the mitochondrial
membrane.

In our experiments, however, this equilibration process was so

fast that it was beyond the resolution of our technique to measure, even at
0°C.

After equilibrium of tracer Pi is achieved, the upper curve in figure 1
represents the net amount of total Pi taken up by mitochondria.

Since extra-

mitochondrial Pi is kept constant in these experiments, the measured Pi
uptake represents the difference between initial rates of mitochondrial uptake
and efflux of Pi.

Accuracy of the measured Pi uptake was increased by allowing
mitochondria to equilibrate with unlabelled Pi for 15 minutes prior to
addition of tracer Pi. This avoids complications (42) such as exchange of label
with portions of the endogenous phosphate pool, or limitation of Pi uptake
due to lower rates of coupled processes (eg co-transport of ions needed to
maintain charge neutrality).

The lower curve in figure 1 represents the amount of background non¬
specific mitochondrial Pi binding.
surface

of

the

inner

This Pi is either bound on the external

mitochondrial

membrane,

or

is

taken

up

by

mitochondria via as yet undefined carriers that are not inhibited by mersalyl
or n-butylmalonate.

Mitochondrial Pi uptake was measured in three groups of rats:

1) Control group: Rats in this group were sham operated but were not
subjected to any ischemic injury.

Figure 1 is a representative assay of

mitochondrial Pi uptake in a control rat.

The upper curve represents the

standard assay, whereas the lower curve represents the background non¬
specific Pi binding.

The corrected Tm of mitochondrial Pi uptake in control

rats was 13.10 + 6.29 nmoles of Pi/mg mitochondrial protein (mean +_ SD)
(n=4). This figure should be distinguished from the Vmax of the PTP which
is obtained by measuring the corrected Tm of mitochondrial Pi uptake with
increasing concentrations of extramitochondrial Pi.

2) Ischemic group: Rats in this group were subjected to 45 minutes of
bilateral renal artery occlusion with no subsequent renal reflow. Figure 2 is a
representative assay of mitochondrial Pi uptake in an ischemic rat.

The

upper curve represents the standard assay, whereas the lower curve
represents the background non-specific Pi binding.

Mitochondrial Pi uptake

in ischemic rats was comparable to that of inhibited controls, with a corrected
Tm of 0.38 + 0.59 nmoles of Pi/mg mitochondrial protein (mean + SD) (n=3).

3) Reperfused group: Rats in this group were subjected to 45 minutes of
bilateral renal artery occlusion followed by 30 minutes of reflow. Figure 3 is a
representative assay of mitochondrial Pi uptake in a reperfused rat.

The

upper curve represents the standard assay, whereas the lower curve
represents the background non-specific Pi binding.

The corrected Tm of

mitochondrial Pi uptake in reperfused rats was 22.2 + 6.17 nmoles of Pi/mg
mitochondrial protein (mean + SD) (n=3).

Representative standard assays of Pi uptake from all 3 groups are
shown in figure 4.

Figure 5 compares the corrected mean values of

mitochondrial Pi uptake among the 3 groups: The corrected Tm of Pi
transport after 45 minutes of ischemia (0.38 + 0.59 nmol Pi/mg-pro) was
markedly less than either uninjured controls (13.10 + 6.29 nmol Pi/mg-pro)
(p=0.016) or reperfused rats (22.2 + 6.17 nmol Pi/mg-pro) (p=0.001).

The

corrected Tm in reperfused rats was not significantly greater than in control
animals (p=0.059).

DISCUSSION

Ischemia and the subsequent reperfusion of ischemic tissue are
thought to play an important pathogenetic role in the tissue injury which
occurs in many clinical settings, such as acute renal failure (ARF).

Working

in a rat model that mimics ARF, Siegel et al. (4) and Stromski et al. (5) have
shown that during 45 minutes of ischemia, renal ATP levels rapidly fall to
less than 10% of their control values and remain low for the duration of the
insult, and that during reperfusion cellular ATP is regenerated in a biphasic
manner: An initial rapid phase returns ATP to 50% of pre-ischemic values
within

15

minutes

of

reflow;

ATP

in

this

phase

is

derived

from

phosphorylation of endogenous AMP and ADP. An ensuing slower phase of
ATP regeneration further increases cellular ATP to 60-65% of pre-ischemic
values after 2 hours of reflow; ATP in this phase is derived from net cellular
resynthesis.

Furthermore, these investigators showed that recovery of

cellular ATP was one of the rate limiting steps in the recovery from the
ischemic injury (10), and that manipulations that increased ATP regeneration
improved the recovery of renal function (4,13,14,18).

ATP is synthesized in the mitochondrial matrix and requires the
mitochondrial uptake of the precursor substrates ADP and inorganic
phosphate (Pi).
likely to

Any alteration in these mitochondrial transport processes is

affect mitochondrial synthesis of ATP.

Understanding

the

disruption of these transport processes would not only help elucidate the
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molecular mechanisms underlying the suboptimal regeneration of ATP
following an ischemic insult, but might also aid in finding novel and
effective therapeutic modalities that would protect the cell from injury
and/or enhance its repair mechanisms during reperfusion.

We therefore elected to investigate the effects of ischemia and
reperfusion on mitochondrial Pi uptake in order to determine whether this
transport process is the rate limiting step in the regeneration of ATP
following an ischemic injury.

Isolation of mitochondria

Mitochondria were isolated from rat renal proximal tubules. This has
not been previously reported.

Proximal tubules are of particular interest as

they are the tubular segment most susceptible to ischemic injury (2).

Their

ATP levels during ischemia and reperfusion have been previously well
defined and shown to be similar to those of whole kidneys (93).

Pi uptake

was measured in mitochondria prepared from control, ischemic and
reperfused rats.

Mitochondrial Pi uptake in control rats

Proximal tubuler mitochondrial Pi uptake in control rats was 13.10 +
6.29 nmoles of Pi/mg mitochondrial protein (mean + SD) at 0°C. This figure
is consistent with the two other reported measurements of mitochondrial Pi
uptake at 0°C: Coty and Pedersen (42) found it to be 16.6 nmoles of Pi/mg

mitochondrial protein in rat liver mitochondria (no error given), and
Carpenter and Shiratori (95) found it to be 12.48 + 5.37 nmoles of Pi/mg
mitochondrial protein in murine renal cortical mitochondria.

Since the Vmax of the PTP (42,45) is significantly greater than both the
Vmax of the ADP/ATP translocator (52) and the maximal rate of ATP
production (53,54), it is therefore unlikely for Pi transport to be the rate
limiting step in the synthesis of ATP under physiologic conditions (45,55).

Mitochondrial Pi uptake in ischemic rats

This is the first reported study of mitochondrial Pi transport under
ischemic conditions.

In rats subjected to 45 minutes of bilateral renal

ischemia with no reflow, renal proximal tubuler mitochondrial Pi uptake
was completely inhibited.

This result is consistent with earlier observations

that i) the PTP is responsible for most of the Pi taken up by mitochondria; ii)
the PTP is pH-dependent; and iii) the mitochondrial pH gradient is dissipated
during ischemia because the respiratory chain is inhibited by anoxia.

Although the dissipation of the mitochondrial pH gradient deprives
the PTP of its driving force (proton gradient) in vivo, this does not explain
the inhibition of mitochondrial Pi uptake as measured in our in vitro system.
Indeed, all our experiments were performed at pH=7.4, whereas cells and
mitochondria during ischemia are known to become acidotic (2).

A pH

gradient was thus artificially created in vitro, but it did not reverse the
inhibition of the PTP.
into an inactive state.

This suggests that ischemia may have altered the PTP
In light of Ligeti and Fonyo's (77) finding that the
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reactivity of the cysteine 42 thiol group is affected by intramitochondrial pH
changes that are probably transmitted through transmembrane steric or
conformational alterations, it would be interesting to speculate that similarly,
inactivation of the PTP may be due to an intramitochondrial acidosis-induced
transmembrane conformational steric change in one or more regions of the
molecule that would prevent the PTP from undergoing a conformational
change required for Pi transport.

Paradies and Ruggiero (71) found the activity of the PTP in 28 monthold rats to be significantly less than that in 5 month-old animals.

These

investigators compared mitochondria from young and aged rats and found
their pH gradients to be the same, their internal exchangeable Pi pools to be
the same, the amount of PTP in their membranes to be the same, the affinity
(Km) for Pi of these PTP to be the same and their respiratory activities to be
the same.

The only difference they detected was in the lipid composition of

their inner membranes. The older rats had a decreased content of the
phospholipid cardiolipin (diphosphatidylglycerol) and the fluidity of the
membrane was consequently decreased. Furthermore, Paradies and Ruggiero
demonstrated that restoring the levels of cardiolipin in the mitochondrial
membrane with the use of acetyl-L-carnitine increased the activity of the PTP
to levels found in the 5 months old rats (98).

Similarly, reconstitution

experiments have demonstrated that the activity of the reconstituted PTP is
strongly

influenced

microenvironment (34).

by

the

lipid

and

protein

composition

of

its

Ischemia is known to induce a loss of membrane

phospholipids and accumulation of membrane

disruptive breakdown

products such as long chain acyl-CoA esters (2).

Such alterations in the

microenvironment of the PTP probably contribute to disrupting its transport

activity during ischemia, but they are unlikely to account for the complete
inhibition of its activity.

Henke and Junge (28) showed that following 60 minutes of ischemia,
the amount of mitochondrial adenine nucleotide translocator remaining in
the inner mitochondrial membrane was only 55% of that measured in
controls, and that the quantitative recovery of this exchanger occurred over
several days, suggesting a slow process of resynthesis.

We did not measure

the amount of PTP present in the mitochondria following the ischemic
insult. It is possible that this amount may be decreased during ischemia, but
this would not explain the complete inhibition of the activity of the PTP. It is
unlikely for the mitochondrial membrane to become completely depleted of
PTP, since mitochondrial Pi uptake was measurable within a few minutes of
reflow (data not shown) and was 70% above control values within 30
minutes of reflow, which would require energy depleted cells to rapidly
resynthesize and incorporate new PTP molecules.

Instead

of postulating an inhibition of mitochondrial

transport

processes, the lack of Pi uptake during ischemia could alternatively be
attributed to Pi leakage through damaged mitochondrial membranes.

We

believe this is an unlikely explanation because: 1) it would require that all
mitochondria incur membrane damages, and that some mitochondria
succeed in repairing this damage within a few minutes (when mitochondrial
Pi uptake is again measurable), a highly improbable biological event; 2) given
the depletion of intramitochondrial Pi stores, the mitochondrial Pi gradient is
more likely to favor Pi uptake - not efflux - through the damaged membrane.
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In summary, mitochondrial Pi uptake in rat renal proximal tubules is
completely inhibited following 45 minutes of ischemia.

The inhibition is

mainly due to the dissipation of the mitochondrial pH gradient and to
inactivation of the PTP possibly through conformational changes in the
carrier molecule itself.

Other factors such as alterations in the membrane

composition, decrease in the mitochondrial content of PTP or damage to the
mitochondrial membrane do not significantly contribute to the inhibition
process.

The inhibition of mitochondrial Pi uptake, however, is unlikely to

be solely responsible for the lack of ATP synthesis during ischemia.

Indeed,

the pH gradient dependent ATP-synthase enzyme is also likely to be inhibited
as anoxia blocks the respiratory chain and dissipates the proton gradient. On
the other hand, the activity of the ADP/ATP translocator during ischemia is
not known. Investigations to assess the effects of ischemia on this carrier are
currently

under

way

in

our

laboratory

(Boydstun

et al.

personal

communication).

Mitochondrial Pi uptake during post-ischemic reperfusion

In rats subjected to 45 minutes of bilateral renal ischemia followed by
30 minutes of renal reflow, mitochondrial Pi uptake not only recovered from
its nadir during ischemia, but was also slightly (although not significantly)
greater than control values.

30 minutes of reflow corresponds to the initial

rapid phase of post-ischemic ATP recovery.

During this phase, ATP is

regenerated from the phosphorylation of the intracellular pool of AMP and
ADP,

which

requires

an

abundant supply

of intramitochondrial

Pi.

Nevertheless, since the Vmax of the PTP in control rats is significantly greater

than the maximal capacity of mitochondria to synthesize ATP, and since
mitochondrial Pi uptake during reflow is at least as great as control values at
a time when ATP regeneration is depressed, it is therefore unlikely for
mitochondrial Pi transport during early reperfusion to be the rate limiting
step in the resynthesis of ATP.

This lends support to previous studies that

had pointed to the total adenine nucleotide (TAN) pool at the end of the
ischemic insult as the possible rate limiting factor in the regeneration of ATP:
TAN levels at the end of the ischemic injury correlate well with the ATP
levels at the end of this initial rapid phase of regeneration (10), and
manipulations
deamination

that
of

increase

adenosine

the
to

TAN
inosine

pool
(13)

(either
or

by

by

blocking

the

inhibiting

the

dephosphorylation of AMP to adenosine (14)) increase cellular ATP levels.

The increased mitochondrial uptake of Pi during post-ischemic reflow
is most likely due to either an increase in the activity of the PTP which, as
detailed above, is determined by the transmembrane pH gradient, or to a
recruitment of a greater number of PTP molecules into their active states,
possibly through intramitochondrial pH induced conformational change(s)
in the carrier molecules themselves.

Interestingly, these conformational

changes which were first suggested by Ligeti and Fonyo (77), function to
inhibit the PTP during ischemia when mitochondria are unable to synthesize
ATP, and to increase the activity of the PTP during reflow to at least control
levels, when cells need to enhance their depleted ATP stores. We would like
to propose a model whereby the mitochondria utilize intramitochondrial pH
as an internal signal to allow the upregulation or downregulation of the
activity of the PTP depending on the mitochondrial need and/or ability to
utilize Pi. Further molecular studies of the topology of the PTP and the steric

properties of its catalytically active sites are required before the existence of
these pH dependent conformational changes could be confirmed and the
validity of our model tested. Nevertheless, intramitochondrial pH itself may
have important regulatory functions.

The transmembrane pH gradient on

the other hand, is known to be utilized by mitochondria for catalyzing the
activity of the ATP synthase, for taking up Pi against a concentration and an
electrical gradient, and for regulating the supply of citric acid intermediates
(37).

In

addition

to

the

transmembrane

pH

gradient

and

to

the

intramitochondrial pH, the increase in the activity of the PTP and/or the
increase in the number of molecules during reflow could also be due to
alterations in the microenvironment.

Paradies and Ruggiero (99) showed

that liver mitochondrial Pi transport was greater in rats that had been treated
for 5 days with thyroxin than in control rats. Conversely, they demonstrated
(100) that this Pi transport was 40% less in rats that had been made
hypothyroid by treatment with 6-n-propyl-2-thiouracil (PTU) for 3-4 weeks,
than in control rats.

In both studies, the only difference found between

control and experimental rats was in their mitochondrial lipid composition.
In rats treated with thyroxin, the phospholipid content of the membrane,
especially cardiolipin, was increased, whereas the cholesterol content was
decreased.

These

alterations

decreased

the

viscosity

of

the

inner

mitochondrial membrane and increased the mobility of its proteins.

The

opposite membrane changes were found in the rats treated with PTU. These
membrane alterations followed 1-3 weeks of treatment with T4 or PTU.

In

contrast, Staub et al. (18) found that the post-ischemic infusion of thyroxin
had an immediate beneficial effect on ATP levels during the slow phase of

ATP recovery.

Experiments are currently under way in our laboratory to

determine the immediate effects of thyroxin infusion on mitochondrial Pi
uptake.

Since Pi transport is unlikely to be rate limiting for the synthesis of

ATP, we are also investigating the effects of thyroxin administration on the
activity

of

the

ADP/ATP

translocase

(Boydstun

et al.

personal

communication).

Future studies will determine mitochondrial Pi uptake at 2 hours of
reflow. This will provide an indication of Pi transport during the slow phase
of post-ischemic ATP regeneration. Since the Vmax of the PTP in control rats
is significantly greater than both the Vmax of the ADP/ATP translocator and
the maximal rate of ATP production, and since Pi uptake at 30 minutes of
reflow is at least as great as control values at a time when ATP synthesis is
depressed, we predict that the mitochondrial Pi uptake at 2 hours of reflow
will not be rate-limiting for the synthesis of ATP. If this uptake at 2 hours of
reflow remains above control values, it would be interesting to speculate
about the reasons for the excess mitochondrial Pi uptake: 1) mitochondria
could be in need for more citric acid cycle intermediates, the uptake of some
of which is coupled to the establishment of the mitochondrial Pi gradient; 2)
the re-activation of the respiratory chain could require excess protons, and Pi
within the matrix serves as a proton-donor to the proton pump; 3) the excess
mitochondrial Pi uptake may be simply a response to the transmembrane pH
gradient or to the existing intramitochondrial pH, without necessarily having
a physiological or a teleological role.

In any case, the excess Pi taken up may have a deleterious effect on
mitochondria. Indeed, it has been shown that after 6 hours of reflow, there is
a progressive deterioration in mitochondrial respiration (101). This coincides

with a gradual accumulation of calcium in mitochondria, which is thought to
be due to a passive movement of calcium across the mitochondrial
membrane secondary to an increase in cytosolic calcium.

However, the

accumulation of calcium does not by itself have any deleterious effects on the
mitochondrial membrane (101,102).

Damage to this membrane occurs only

when Pi is also accumulated in mitochondria (103), at which point calcium
phosphate precipitates appear in the matrix and are seen as granular densities
under electron microscopy (24,25).
reperfusion

may

contribute

to

Thus the excess Pi taken up during

the

deleterious

processes

that

affect

mitochondria during the later stages of reflow. In theory, partial inhibition of
this transport process during reperfusion may prevent mitochondrial
dysfunction and the ensuing cell injury.

Summary

In summary, we isolated mitochondria from renal proximal tubules of
control,

ischemic

and

reperfused

rats,

and

determined

Pi

uptake.

Mitochondrial Pi uptake was inhibited during ischemia, but recovered to at
least

control

values

during

reperfusion.

Thus,

it

is

unlikely

that

mitochondrial Pi uptake is the rate-limiting step in the post-ischemic
resynthesis of ATP.

It may

mitochondria during reperfusion.

however have a

detrimental

effect on
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LEGEND

Figure 1: Mitochondrial Pi uptake in a control rat. Control rats were sham
operated but were not subjected to any ischemic insult. The upper
curve represents the standard assay; the lower curve represents the
accompanying control assay, in which the mitochondria were pre¬
incubated with the 2 mitochondrial Pi transport inhibitors mersalyl
and n-butylmalonate prior to the addition of the tracer Pi, to determine
background non-specific binding of Pi to mitochondria.

Figure 2: Mitochondrial Pi uptake in ischemic rats. Ischemic rats were
subjected to 45 minutes of bilateral renal artery occlusion with no
subsequent reflow. The upper curve represents the standard assay; the
lower curve represents the accompanying control assay for background
non-specific binding of Pi to mitochondria.

Figure 3: Mitochondrial Pi uptake in reperfused rats. Reperfused rats were
subjected to 45 minutes of bilateral renal artery occlusion followed by
30 minutes of reflow. The upper curve represents the standard assay;
the lower curve represents the accompanying control assay for
background non-specific binding of Pi to mitochondria.

Figure 4: Mitochondrial Pi uptake in control, ischemic and reperfused rats. A
representative standard assay from each group is shown.

Figure 5: Comparison of the corrected mean values of mitochondrial Pi
uptake (corrected Tm's) between control, ischemic and reperfused rats.
Error bars represent standard errors.
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